The necessity of a more aggressive initial surgical treatment in patients with mesothelioma of the testicular tunica vaginalis

Publication date: Available online 12 October 2019Source: Annals of Medicine and SurgeryAuthor(s): Clement Brun, Sophie Giusiano, Khady Thiam, Julien Guinde, Marios Froudarakis, Philippe AstoulAbstractMesothelioma of the tunica vaginalis of the testis (MTVM) is a rare tumor encountering for less than 1% of mesothelioma. Patients suffering from these tumors have poor survival due to local and distant metastasis despite treatment. Actually, no specific treatment recommendations exist for this tumor, yet radical orchidectomy is the gold standard in limited disease. We herein report the case of a 71 patient with MTVM who underwent radical orchidectomy without inguinal lymph node dissection and recurred 2 years later with metastasis in pelvic and mediastinal lymph nodes. Despite systemic chemotherapy combining pemetrexed, bevacizumab and Cisplatinum, the disease relapsed eight months later with multiple metastatic lung nodules leading to a treatment shift. We believe that systematic inguinal-iliac lymph node resection should be included in the initial treatment of this tumor.
Source: Annals of Medicine and Surgery - Category: General Medicine Source Type: research

Related Links:

Conditions:   Pleural Biphasic Mesothelioma;   Pleural Epithelioid Mesothelioma;   Stage I Pleural Malignant Mesothelioma AJCC v8;   Stage IA Pleural Malignant Mesothelioma AJCC v8;   Stage IB Pleural Malignant Mesothelioma AJCC v8;   Stage II Pleural Malignant Mesothelioma AJC C v8;   Stage IIIA Pleural Malignant Mesothelioma AJCC v8 Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Proced...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The Miami Cancer Institute on Thursday will begin using the innovative Tumor Treating Fields device for patients with malignant pleural mesothelioma. It is the first new treatment approved for mesothelioma by the U.S. Food and Drug Administration in more than 15 years. “This is actually pretty exciting for us,” Dr. Rupesh Kotecha, the radiation oncologist who will oversee the treatment protocol in Miami, told The Mesothelioma Center at Asbestos.com. “It’s another tool in our armamentarium. It’s something we can offer patients that has shown a real benefit.” The noninvasive Tumor Treating...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Although malignant mesothelioma (MM) is rare among thoracic malignancies, approximately 1500 and 3000 patients are newly diagnosed each year in Japan and the United States [1], respectively. Treatment of MM, including surgery, radiotherapy, and chemotherapy, is recommended according to stage, performance status, pulmonary function, complications, and patient preference. First-line chemotherapy for advanced MM involves a combination of cisplatin and pemetrexed as the standard treatment. Although this combination has been proven to prolong survival over cisplatin alone in a phase III trial (12.1 months vs.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Dr. Giovanni Ceresoli doesn’t think Tumor Treating Fields will work for every patient with mesothelioma cancer, but he knows it will work for some. They are in his clinic. As the principal investigator of the multicenter clinical trial that led to approval by the U.S. Food and Drug Administration in May, Ceresoli has played a major role in the development of this latest mesothelioma treatment. “It might be too early to say this is a major breakthrough — we need more data — but I hope it is. I know it’s something promising, very promising,” Cerosoli told The Mesothelioma Center at Asbest...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
The Mesothelioma and Radical Surgery Trial (MARS 2) aims to evaluate a surgical procedure by comparing chemotherapy and surgery against chemotherapy alone. The pilot study for MARS 2 evaluated the viability of...
Source: Trials - Category: General Medicine Authors: Tags: Research Source Type: research
Doctors at the Swiss Group for Clinical Cancer Research in Zurich, Switzerland, have uncovered a novel, anti-tumor compound that could become a needed second-line treatment for pleural mesothelioma cancer. Their recent multicenter phase II clinical trial conducted in Switzerland and Italy revealed the safety and efficacy of lurbinectedin, a synthetically produced agent that inhibits the growth of mesothelioma cells. “We believe this could represent a new treatment option for pleural mesothelioma,” Dr. Yannis Metaxas, oncologist at Kantonsspital Graubunden outside Zurich, told The Mesothelioma Center at Asbestos...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Peritoneal mesothelioma of both borderline and malignant subtypes can be successfully managed with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. The incidence of diffuse malignant peritoneal mesothelioma has statistically increased over time in Sweden; fortunately likewise, the overall survival has also increased statistically in part due to the implementation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. AbstractThe study aim was to report survival and morbidity of all patients in Sweden with peritoneal mesothelioma treated with cytoreductive surgery (CRS) and hyperthermic ...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Conclusion: This is the first description of gC1qR expression in MPM. The data identify gC1qR as a potential new prognostic factor in patients treated with surgery and chemotherapy.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Authors: Kuribayashi K, Doi H, Kijima T Abstract Introduction: The surgical arm of the Mesothelioma and Radical Surgery (MARS) trial involved a multimodal approach, with combined therapy consisting of chemotherapy, complete gross resection, and radiation therapy. However, the MARS trial did not compare surgery with chemotherapy, and the survival and quality of life outcomes of this trial's surgical arm were inferior to those of the non-surgical arm. Methods for achieving complete gross resection (macroscopic complete response [MCR]) include extrapleural pneumonectomy (EPP), wherein the pleura, lung, diaphragm, and ...
Source: Expert Review of Respiratory Medicine - Category: Respiratory Medicine Tags: Expert Rev Respir Med Source Type: research
Kocher Schmid Peng Malignant pleural mesothelioma (MPM) is a lethal cancer with limited treatment options. No targeted therapy has emerged yet. Here, we performed an integrated molecular characterization of patient tumors in the TCGA dataset, and discovered that endoplasmic reticulum (ER) stress and the adaptive unfolded protein response (UPR) signaling are characteristically deregulated in MPM. Consequently, pharmacological perturbation of ER stress/UPR axis by HA15, an agent that induces persistent proteotoxic stress in the ER, selectively suppresses the viability of MPM cells including those refractory to stan...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
More News: Alimta | Asbestosis | Avastin | Chemotherapy | General Medicine | Mesothelioma